Oliver Sartor
Oliver Sartor | |
|---|---|
| Alma mater | Tulane University |
| Scientific career | |
| Fields | Oncology |
| Institutions | Tulane School of Medicine |
Oliver Sartor is an American oncologist and research scientist. He is currently the chair of the genitourinary cancer disease group and director of radiopharmaceutical clinical trials at Mayo Clinic Rochester. He was previously the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews.[1] Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology.[2]
Education and career[edit]
Sartor attended Tulane University, where he received his MD in 1982 with honors. He then served as an intern at the University of Pennsylvania. After the internship, he served a residency in internal medicine at Tulane Medical School and then completed a medical oncology fellowship at the National Cancer Institute (NCI) in 1989.[3]
He joined the faculty at NCI, where he became a senior investigator mainly focusing on novel therapeutics for patients with advanced prostate cancer. He served as faculty at the NCI from 1990 till 1993, when he later returned to Louisiana and joined the faculty of LSU Medical School in Shreveport as an associate professor.[4][5] In 1998, Sartor became professor of oncology, director at the Stanley S, Scott Cancer Center, and a chief of Hematology/Oncology section at LSU Medical School in New Orleans. He was named the co-director of Louisiana Cancer Research Consortium in 2002. Sartor left LSU after Hurricane Katrina and in 2006 joined the faculty of Harvard Medical School and the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute.[6][7] In January 2008, Sartor was appointed as professor in the Medicine and Urology Departments at Tulane University. He was later appointed the medical director at the Tulane Cancer Center in July 2010 and has served as assistant dean for oncology since 2016.[8] He has served as medical oncology co-chair of the Genitourinary Committee of NRG (formerly RTOG) since 2006 and has served on the NCI Board of Scientific Counselors (Clinical and Epidemiology) since 2014.[9]
Research[edit]
Throughout his academic career, Sartor has worked as a researcher, almost exclusively focused on prostate cancer. He has earned international recognition, particularly as an expert in advanced prostate cancer. He has published extensively on both prostate cancer translational studies and clinical trials that involve novel agents.[10]
Sartor was the PI or co-PI on four prostate cancer studies pivotal for FDA drug approval including Samarium-153 EDTMP,[11] Cabazitaxel,[12] Radium-223,[13] and Leuprolide Acetate 30 mg sustained release (Eligard).[14] In addition he has served as chair of the Data Monitor Committee for numerous phase III trials, including 6 trials pivotal for FDA approval.[15][failed verification]
References[edit]
- ^ Sartor, Oliver. "Preliminary Data from the PROCEED Registry- Oliver Sartor". www.urotoday.com. Retrieved 6 September 2018.
- ^ "A. Oliver Sartor, MD | medicine". medicine.tulane.edu. Retrieved 6 September 2018.
- ^ "An Update on New Therapies for mCRPC: Interview with Oliver Sartor, MD". www.renalandurologynews.com. Retrieved 6 September 2018.
- ^ Rosenthal, Eric T. (October 2005). "Rallying to Oncology Patients & Cancer Care Professionals, Two New Orleans Cancer Center Directors Share Their Stories". Oncology Times. 27 (19): 26–28. doi:10.1097/01.COT.0000289684.23125.e5.
- ^ Sartor, Oliver (June 2002). "Editorial". Clinical Prostate Cancer. 1: 5. doi:10.3816/CGC.2002.n.001. Retrieved 6 September 2018.
- ^ "About Oliver Sartor | Tulane Urology Garden District". Tulane Urology Garden District. Retrieved 6 September 2018.
- ^ "Pulled up by his New Orleans roots - The Boston Globe". archive.boston.com. Retrieved 6 September 2018.
- ^ Chustecka, Zosia (February 1, 2012). "MDV3100 in Prostate Cancer 'Exceeded Expectations'". Medscape. Retrieved 6 September 2018.
- ^ "Genitourinary Cancer". www.rtog.org. Retrieved 24 September 2018.
- ^ "'Desperation Oncology': When Patients Are Dying, Some Cancer Doctors Turn to Immunotherapy". The New York Times. Retrieved 6 September 2018.
- ^ Higano, Celestia S.; Quick, Donald P.; Bushnell, David; Sartor, Oliver (2008). "Safety Analysis of Repeated High Doses of Samarium-153 Lexidronam in Men with Hormone-Naive Prostate Cancer Metastatic to Bone". Clinical Genitourinary Cancer. 6 (1): 40–45. doi:10.3816/CGC.2008.n.007. ISSN 1558-7673. PMID 18501082.
- ^ Oudard, Stéphane; Fizazi, Karim; Sengeløv, Lisa; Daugaard, Gedske; Saad, Fred; Hansen, Steinbjørn; Hjälm-Eriksson, Marie; Jassem, Jacek; Thiery-Vuillemin, Antoine (2017-10-01). "Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA". Journal of Clinical Oncology. 35 (28): 3189–3197. doi:10.1200/JCO.2016.72.1068. ISSN 1527-7755. PMID 28753384.
- ^ Vuong, Winston; Sartor, Oliver; Pal, Sumanta K (2014). "Radium-223 in metastatic castration resistant prostate cancer". Asian Journal of Andrology. 16 (3): 348–353. doi:10.4103/1008-682X.127812. ISSN 1008-682X. PMC 4023358. PMID 24713838.
- ^ Crawford, E; Moul, Judd; Sartor, Oliver; Shore, Neal (2015-08-18). "Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: Achieving testosterone levels below 20 ng/dl". Expert Opinion on Drug Metabolism & Toxicology. 11 (9): 1465–1474. doi:10.1517/17425255.2015.1073711. PMID 26293510.
- ^ Sartor, Oliver. "In the News". ProstateCancerResearch.org. Retrieved 6 September 2018.